New Clinical Studies show Improved Melanoma Detection by US clinicians with Nevisense

"Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate making early detection critical to survival. These studies show a significant reduction of missed melanomas from ~7% to less than 1%, a further indication of the clinical value Nevisense can bring by helping clinicians identify melanomas and improve performance across the board. This is the first time this type of study has been performed and we are pleased with the results," stated Dr. Darrell S. Rigel, Clinical Professor, Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine. "These results further demonstrate the benefits of early melanoma detection with Nevisense, and I am pleased that we are able to share our findings with the clinical community demonstrating the benefits of this technology for patients."

STOCKHOLM, 16/09/2020 (informazione.news - comunicati stampa - scienza e tecnologia)

" ," stated Dr. Darrell S. Rigel , Clinical Professor, Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine. " ."

" ," said Simon Grant , CEO of SciBase.  " ."


Simon Grant , CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com 

Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/new-clinical-studies-show-improved-melanoma-detection-by-us-clinicians-with-nevisense,c3194683

The following files are available for download: